B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Kimio Yonesaka(Kindai University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Shiki Takamura(Kindai University), Yasutaka Chiba(Kindai University Hospital), Kazuko Sakai(Kindai University Sakai Hospital), Hidetoshi Hayashi(Kindai University), Naoki Takegawa(Hyogo Prefectural Cancer Center), Takafumi Okabe(Dana-Farber Cancer Institute), Michiko Yamato(Daiichi Sankyo (Germany)), Osamu Maenishi(Kindai University), Koji Haratani(Dana-Farber Cancer Institute), Takayuki Takahama(Kindai University), Hiroyasu Kaneda(Osaka City University), Kenji Hirotani(Daiichi Sankyo (Germany)), Masayuki Takeda(Kindai University), Ryoji Kato(Kindai University), Kaoru Tanaka(Kindai University), Keita Kudo(Osaka Minami Medical Center), Hitomi Sakai(Kindai University Hospital), Yoshikazu Hasegawa(Izumi City General Hospital), Masaaki Miyazawa(Kao Corporation (Japan)), Sigeki Kato(Kindai University), Kazuto Nishio(Kindai University Sakai Hospital)
Cited by 169
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k